Beximco Pharmaceuticals Ltd.

Bangladesh′s Beximco Pharma starts marketing its products in Sri Lanka

Bangladesh′s leading drug manufacturer Beximco Pharmaceuticals Ltd (BPL) has formally commenced marketing its products in Sri Lanka.

Initially the company has started export of six (6) products of four (4) generics and also registering 28 more new and exciting products in Sri Lankan market. Emerchemie NB, one of the leading pharmaceutical distributors of Sri Lanka is acting as the agent of Beximco Pharma.

Beximco Pharma is a member of Beximco Group, which is the largest industrial conglomerate of Bangladesh, having 11 listed and 13 private companies and over 25,000 employees. Beximco Pharma is the first and only company in Bangladesh listed on the London Stock Exchange, the second largest stock exchange in the world. The company has an annual turnover of US$ 50 million.

Beximco Pharma started its journey in 1980 with manufacturing and marketing of under licensee products of Bayer AG, Germany and Upjohn Inc. of the USA and now meets 10 percent of country′s total medicine need. The company manufactures and markets its own ‘branded generics’ for almost all diseases from AIDS to cancer, from infection to asthma and from hypertension to diabetes etc.

Beximco Pharma is the largest pharmaceutical exporter of Bangladesh. In Bangladesh BPL is the only pharmaceutical company to receive National Export Trophy (Gold) for consecutive three years for its outstanding export performance. So far Beximco Pharma has exported its products to 19 countries including Pakistan, Singapore, Kenya, Myanmar, Nepal, Vietnam, Yemen etc. The company also supplies medicines to some of the world renowned hospitals and institutions like Raffles Hospital, and K K Women & Children Hospital in Singapore, MEDS and Kenyatta Hospital in Kenya, Jinnah Hospital, Agha Khan Hospital and Shaukat Khanum Memorial Hospital in Pakistan. Beximco Pharma has also supplied its IV & finished formulation products to WHO and UNICEF. In 2005, BPL received ‘SAARC Country Gold Award-2005 for Industrial Excellence’ from the Ceylon National Chamber of Industries (CNCI). This award was given on the basis of certain criteria including productivity standards, value addition, quality control, employee benefits and relationships, respect for the environment, cleaner production and social welfare.

To meet the future demand and to develop a strong export market in USA and Europe, BPL has now invested US $50 million on a new state-of-the-art manufacturing plant, conforming to USFDA and UK MHRA standards. This new plant will also offer contract manufacturing facility to leading pharmaceutical companies, especially to the European and US Pharmaceutical companies.

To-day, Beximco Pharmaceuticals Ltd. is privileged to co-operate with EMERCHEMIE NB (Ceylon) Limited in an ambit to make available their Pharmaceutical Specialties to the Sri Lankan Doctors and Patients. It is very much the intention of Beximco Pharma to serve the needs of the Sri Lankan population through effective and affordable medicines.